

Haematologica
HAEMATOL/2018/191429
Version 3

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma

Rémy Gressin, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Sylvain Carras, Emmanuelle Tchernonog, Anna Schmitt, Roch Houot, Caroline Dartigeas, Jean Michel Pignon, Selim Corm, Anne Banos, Christiane Mounier, Jehan Dupuis, Margaret Macro, Joel Fleury, Fabrice Jardin, Clementine Sarkozy, Gandi Damaj, Pierre Feugier, Luc Matthieu Fornecker, Cecile Chabrot, Veronique Dorveaux, Krimo Bouabdallah, Sandy Amorin, Reda Garidi, Laurent Voillat, Bertrand Joly, Philippe Solal Celigny, Nadine Morineau, Marie Pierre Moles, Hacene Zerazhi, Jean Fontan, Yazid Arkam, Magda Alexis, Vincent Delwail, Jean Pierre Vilque, Loic Ysebaert, Steven Le Gouill, and Mary B. Callanan

Disclosures: Author COI: Author 1 - Remy Gressin Consulting or Advisory Role from Celgene Travel from Sandoz, Celgene and Novartis Author 2 - Nicolas Daguindau, no COI to be declare Author 3 - Adrian Tempescul, no COI to be declare Author 4 - Anne Moreau, no COI to be declare Author 5 - Sylvain Carras, no COI to be declare Author 6 - Emmanuelle Tchernonog, no COI to be declare Author 7 - Anne Schmitt, no COI to be declare Author 8 - Roch Houot, no COI to be declare Author 9 - Caroline Dartigeas Consulting or Advisory Role from Roche and Janssen Travels from Roche Pharma AG and Mundipharma Author 10 - Jean Michel Pignon, no COI to be declare Author 11 - Selim Corm, no COI to be declare Author 12 - Anne Banos, no COI to be declare Author 13 - Christiane Mounier, no COI to be declare Author 14 - Jehan Dupuis, no COI to be declare Author 15 - Margaret Macro Travels from Celgene, Janssen, Amgen, Takeda, BMS and Sanofi Author 16 - Joel Fleury, no COI to be declare Author 17 - Fabrice Jardin, no COI to be declare Author 18 - Clementine Sarkozy Travels from rocha and takeda; Author 19 - Gandhi Damaj Honoraria from Janssen Consulting or Advisory Role from Roche Research Funding from Mundipharma Author 20 - Pierre Feugier Honoraria from Roche Consulting or Advisory Role from Roche Author 21 - Luc-matthieu Fornecker Honoraria from Roche, Takeda, Gilead Sciences, Janssen, BMS and SERVIER Travels from Roche, Gilead Sciences and Janssen Author 22 - Cecile Chabrot, no COI to be declare Author 23 - Veronique Dorvaux, no COI to be declare Author 24 - Krime Bouabdallah, no COI to be declare Author 25 - Sandy Amorin, no COI to be declare Author 26 - Reda Garidi, no COI to be declare Author 27 - Laurent Voillat, no COI to be declare Author 28 - Bertrand Joly, no COI to be declare Author 29 - Philippe Solal Celigny Consulting or Advisory from Roche Author 30 - Nadine Morineau, no COI to be declare Author 31 - Marie Pierre Moles, no COI to be declare Author 32 - Hacene Zerazhi, no COI to be declare Author 33 - Jean Fontan, no COI to be declare Author 34 - Yazid Arkam, no COI to be declare Author 35 - Magda Alexis, no COI to be declare Author 36 - Vincent Delwail, no COI to be declare Author 37 - Jean-Pierre Vilque, no COI to be declare Author 38 - Loic Ysebaert Consulting or Advisory Role from Janssen and Gilead Sciences Author 39 - Steven Le Gouill Honoraria from Janssen-Cilag, SERVIER and Roche Research Funding from Roche Author 40 - Mary Callanan, research funding from Janssen-Cilag and Mundipharma.

Contributions: Conception and design: Rémy Gressin, Mary B. Callanan, Steven Le Gouill Provision of study materials or patients; all the authors Collection or assembly of data: all the authors and the Lysa group Data analysis and interpretation: Rémy Gressin, Mary callanan Manuscript writing: Rémy Gressin and Mary B. Callanan Final approval of manuscript: all the authors